- Home
- ONMD vs BLRX Comparison
ONMD vs BLRX Comparison
Compare ONMD & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- BLRX
- Stock Information
- Founded
- ONMD 2006
- BLRX 2003
- Country
- ONMD United States
- BLRX Israel
- Employees
- ONMD N/A
- BLRX N/A
- Industry
- ONMD
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONMD
- BLRX Health Care
- Exchange
- ONMD Nasdaq
- BLRX Nasdaq
- Market Cap
- ONMD 12.8M
- BLRX 15.3M
- IPO Year
- ONMD N/A
- BLRX 2011
- Fundamental
- Price
- ONMD $0.56
- BLRX $4.49
- Analyst Decision
- ONMD
- BLRX Strong Buy
- Analyst Count
- ONMD 0
- BLRX 2
- Target Price
- ONMD N/A
- BLRX $19.00
- AVG Volume (30 Days)
- ONMD 25.4M
- BLRX 190.6K
- Earning Date
- ONMD 05-14-2025
- BLRX 08-14-2025
- Dividend Yield
- ONMD N/A
- BLRX N/A
- EPS Growth
- ONMD N/A
- BLRX N/A
- EPS
- ONMD N/A
- BLRX N/A
- Revenue
- ONMD $532,000.00
- BLRX $22,340,000.00
- Revenue This Year
- ONMD N/A
- BLRX N/A
- Revenue Next Year
- ONMD N/A
- BLRX N/A
- P/E Ratio
- ONMD N/A
- BLRX N/A
- Revenue Growth
- ONMD N/A
- BLRX 91.68
- 52 Week Low
- ONMD $0.30
- BLRX $2.30
- 52 Week High
- ONMD $1.60
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- ONMD 56.14
- BLRX 51.09
- Support Level
- ONMD $0.34
- BLRX $4.35
- Resistance Level
- ONMD $0.66
- BLRX $4.64
- Average True Range (ATR)
- ONMD 0.09
- BLRX 0.40
- MACD
- ONMD 0.02
- BLRX -0.07
- Stochastic Oscillator
- ONMD 40.17
- BLRX 47.30
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its innovative solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols and paves the way for Real World Evidence.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.